Merck transfers diabetes and thyroid business from Takeda to its own operations in Russia

2 February 2015

Germany’s Merck KGaA (MRK: DE) has transferred responsibility for its diabetes and thyroid portfolio from marketing partner Takeda (TYO: 4502) to Merck Serono in Russia.

This is part of Merck Serono’s commercial strategy to expand into emerging markets, and to provide quality products to meet the increasing needs of Russian patients with diabetes and thyroid diseases.

Branding of products will not change, and products will be manufactured and distributed through the same channels. The company recently expanded its retail sales force in anticipation of the change, and promotion and marketing will be handled by a new local business unit.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK